MA43284A - Composés et leurs méthodes d'utilisation - Google Patents
Composés et leurs méthodes d'utilisationInfo
- Publication number
- MA43284A MA43284A MA043284A MA43284A MA43284A MA 43284 A MA43284 A MA 43284A MA 043284 A MA043284 A MA 043284A MA 43284 A MA43284 A MA 43284A MA 43284 A MA43284 A MA 43284A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258222P | 2015-11-20 | 2015-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43284A true MA43284A (fr) | 2018-09-26 |
Family
ID=58717898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043284A MA43284A (fr) | 2015-11-20 | 2016-11-18 | Composés et leurs méthodes d'utilisation |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20200306262A1 (fr) |
| EP (1) | EP3377070A4 (fr) |
| MA (1) | MA43284A (fr) |
| WO (1) | WO2017087864A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| HRP20200995T1 (hr) | 2013-04-17 | 2020-11-27 | Sage Therapeutics, Inc. | 19-nor neuroaktivni steroidi za metode liječenja |
| HRP20190232T1 (hr) | 2013-04-17 | 2019-03-22 | Sage Therapeutics, Inc. | 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| WO2014169831A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| SMT202100229T1 (it) | 2013-07-19 | 2021-05-07 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| SMT202100048T1 (it) | 2013-08-23 | 2021-03-15 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| WO2015195962A1 (fr) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, leurs compositions et utilisations |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| AU2015331749A1 (en) | 2014-10-16 | 2017-05-04 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| JP6742308B2 (ja) | 2014-10-16 | 2020-08-19 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| ES2793237T3 (es) | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN109689673B (zh) | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| EP3720867A1 (fr) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| US20230346801A1 (en) | 2020-03-25 | 2023-11-02 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090264443A1 (en) * | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| US20140050789A1 (en) * | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| BR112015014397B1 (pt) * | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
| WO2014108808A2 (fr) * | 2013-01-09 | 2014-07-17 | Henry James Lorne | Formulations pharmaceutiques pour le traitement et la prévention de la neuropathologie et de la neurodégénérescence induites par un traumatisme |
| CA2831054C (fr) * | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations et procedes pour leur utilisation dans le traitement d'une neuropathologie et d'une neurodegeneration en raison d'une lesion traumatique |
| SMT202100229T1 (it) * | 2013-07-19 | 2021-05-07 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| EP3188734A4 (fr) * | 2014-09-02 | 2018-01-10 | The Texas A&M University System | Méthode de traitement de l'intoxication par organophosphates |
| ES2793237T3 (es) * | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
-
2016
- 2016-11-18 US US15/777,394 patent/US20200306262A1/en not_active Abandoned
- 2016-11-18 EP EP16867267.3A patent/EP3377070A4/fr not_active Withdrawn
- 2016-11-18 MA MA043284A patent/MA43284A/fr unknown
- 2016-11-18 WO PCT/US2016/062874 patent/WO2017087864A1/fr not_active Ceased
-
2021
- 2021-08-13 US US17/401,787 patent/US20210369734A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210369734A1 (en) | 2021-12-02 |
| US20200306262A1 (en) | 2020-10-01 |
| EP3377070A4 (fr) | 2019-07-10 |
| WO2017087864A1 (fr) | 2017-05-26 |
| EP3377070A1 (fr) | 2018-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| EP3356381A4 (fr) | Dérivés nucléotidiques et leurs méthodes d'utilisation | |
| EP3373969A4 (fr) | Composés interagissant avec le glycane et méthodes d'utilisation | |
| EP3504213A4 (fr) | Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation | |
| EP3429635A4 (fr) | Composés anti-crispr et leurs procédés d'utilisation | |
| EP3463381A4 (fr) | Dérivés nucléotidiques et leurs méthodes d'utilisation | |
| EP3700527A4 (fr) | Inhibiteurs de papd5 et leurs méthodes d'utilisation | |
| EP3368016A4 (fr) | Polysaccharides réduits et oxydés et leurs méthodes d'utilisation | |
| EP3319611A4 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| EP3383430A4 (fr) | Anticorps et leurs méthodes d'utilisation | |
| EP3337517A4 (fr) | Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation | |
| EP3383431A4 (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
| MA42302A (fr) | Lactames bicycliques et leurs méthodes d'utilisation | |
| EP3317273A4 (fr) | Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci | |
| EP3436022A4 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA39915B1 (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| EP3349579A4 (fr) | Composés hétéroaryle substitués et leurs méthodes d'utilisation | |
| MA42118A (fr) | Benzamides substitués et leurs méthodes d'utilisation | |
| EP3710006A4 (fr) | Composés hétéroaryle substitués et leurs méthodes d'utilisation | |
| EP3019484A4 (fr) | Composés thérapeutiquement actifs et leurs méthodes d'utilisation | |
| MA46422A (fr) | Oligonucléotides modifiés et méthodes d'utilisation | |
| MA41642A (fr) | Variants de protoxine ii et méthodes d'utilisation | |
| EP3341218C0 (fr) | Compositions de moulage et leurs méthodes d'utilisation | |
| MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation | |
| EP3468555A4 (fr) | Composés antimicrobiens et leurs procédés d'utilisation |